Se
Second Sight
Sylmar CAFounded 200350 employees
Private CapbiotechAcquiredOphthalmology
Platform: Argus Retinal
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| SEC-7279 | SEC-7279 | Phase 2 | 2 | IL-13 | MelanomaOvarian Ca | ||
| Motanaritide | SEC-5096 | Approved | 1 | FLT3 | DLBCLAML | ||
| Pemifutibatinib | SEC-9241 | Phase 2/3 | 2 | IL-13 | ADPKD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)